Articles tagged with Vaccine Development
Researchers from POSTECH and KRICT created a 3D artificial lung using bioprinting technology, closely mimicking the human respiratory tract. This model allows for accurate testing of COVID-19 drugs and development of therapeutic treatments, potentially shortening the drug development process to under 5 years.
A Phase 1 study evaluates an individualized neoantigen therapy, showing it is well-tolerated and boosts immune activity against cancer-causing cells. The therapy induces multiple forms of T cell proliferation and sustained responses in patients with melanoma and lung cancer.
Researchers at Stanford University developed a nanoparticle platform to make vaccines more effective against various pathogens. The platform allows for the elicitation of different immune responses, enabling the identification of the most effective type of protection.
Researchers at the University of Houston have developed two nasal sprays, NanoSTING and NanoSTING-SN, to prevent respiratory virus transmission. NanoSTING is an immune activator that can protect against multiple viruses, while NanoSTING-SN is a pan-coronavirus vaccine that can prevent transmission to unvaccinated individuals.
A team of researchers from the University of York and Hull York Medical School has developed a new, safe and effective way to infect volunteers with the parasite that causes leishmaniasis, allowing for the testing of vaccines and preventative measures.
Researchers at La Jolla Institute for Immunology have discovered immune cells, such as tissue resident memory cells, in the upper airway that can fight infections and build long-term immunity. These findings may lead to better vaccines and a deeper understanding of immunity against respiratory pathogens.
A University of Vienna research team has developed a new generation of RNA building blocks for high-density microarrays, significantly reducing production time. This breakthrough enables faster synthesis and analysis of RNA molecules, opening up new opportunities for medical research and non-invasive diagnostics.
Researchers at WashU Medicine developed a nasal COVID-19 vaccine that halted transmission in hamsters, showing promise for controlling respiratory infections. The vaccine targeted the virus's entry points in the nose and mouth, reducing viral replication and preventing spread.
A new study on malignant catarrhal fever (MCF) in cattle reveals the mechanisms of AlHV-1 infection and identifies a crucial viral gene involved in disease development. The research provides a promising basis for developing an effective vaccine against this devastating bovine disease.
Researchers have created nanoparticles that can release drugs in multiple stages, allowing for more precise targeting of specific sites in the body. This technology has the potential to enhance the effectiveness of therapeutics and reduce side effects, paving the way for new treatments and improved patient care.
Researchers at George Mason University's Center for Infectious Disease Research have made a breakthrough in finding a functional cure for HIV. Using an HIV-like virus particle called HIV Rev-dependent lentiviral vector, the team was able to reduce viral reservoirs and boost the immune system to produce antiviral neutralizing antibodies.
A new study has found that 90-95% of participants produced strong T-cell responses after exposure to adenoviral vaccines in a lab setting. This unexpected finding may have implications for the effectiveness and safety of future COVID-19 vaccines, as well as other infectious diseases.
Researchers developed a universal influenza vaccine that targets the internal structural proteins of the virus, providing lifetime immunity against evolving viruses. Six out of 11 nonhuman primates inoculated with the vaccine survived exposure to the H5N1 virus, while unvaccinated primates succumbed to the disease.
A new approach in vaccine research, adaptive platform trials (APTs), offers a flexible adjustment of study design during ongoing clinical trials. This allows for quick adaptation to new developments and enables the recruitment of large numbers of participants across different countries.
Scientists from Hackensack Meridian Health have identified a new potential pathway for developing vaccines against tuberculosis by targeting marginal zone B (MZB) cells, a natural response to TB infection. The discovery suggests that boosting MZB cell activity could provide reliable and durable protection against the disease.
The University of Pennsylvania team has pioneered a novel 'one-pot platform' to produce mRNA delivery particles, accelerating the synthesis process and enabling precise targeting of specific organs. The approach leverages click-like chemistry to create lipid nanoparticles with biodegradable components, enhancing mRNA delivery into cells.
Researchers at Trinity College Dublin have made a breakthrough in understanding how to improve vaccine responses against the potentially deadly MRSA bacterium. By targeting the immune-suppressive molecule IL-10, they improved the ability of vaccines to protect against infection and reduce bacterial clearance.
A new urine-based test accurately measures high-risk HPV16 E7 oncoproteins in urine to detect cervical cancer. The test shows promise in making cervical cancer screening more accessible and less invasive.
Researchers at Cornell University have developed a bioelectric device that can detect and classify new coronavirus variants, identifying those most harmful. The device uses a biomembrane on a microchip to recreate the cellular environment for infection, allowing for quick characterization and analysis of variant mechanics.
Researchers have developed a humanized mouse model with a fully functional human immune system, enabling the study of immunotherapy development, disease modeling, and vaccine development. The new model, called TruHuX, mounts specific antibody responses and can develop full-fledged systemic lupus autoimmunity.
Researchers at Butantan Institute and collaborators developed a more potent version of the BCG vaccine, which protects against tuberculosis by inducing a strong immune response. The new formulation protected animals for a significantly longer period than conventional BCG.
AlphaFold's groundbreaking ability to predict protein structures is set to transform predictive medicine, enabling the development of personalized vaccines and adaptive clinical trials. However, the review also highlights crucial challenges and ethical considerations surrounding AI integration with clinical data.
Researchers at the University of the Witwatersrand have developed a modified BCG vaccine that shows enhanced protection against tuberculosis in mice. The new vaccine candidate could potentially replace or boost existing TB vaccines, providing a novel solution to the global health crisis.
Researchers used single-cell sequencing technology to study immune responses in healthy adult volunteers exposed to SARS-CoV-2. They discovered unique immune responses associated with resisting sustained viral infection and disease, including activation of specialized mucosal immune cells and a reduction in inflammatory white blood cells.
A new study analyzed over 14,600 scientific publications funded by more than $4 billion in NIH grants, revealing key research topics such as clinical trials, vaccine distribution, and virology. The findings suggest that half of the funding went to five states: North Carolina, Washington, New York, California, and Massachusetts.
Prof. Tomer Hertz's research will measure immune responses to polioviruses using a novel antigen array, facilitating rapid analysis in countries where polio has yet to be eradicated. The funding aims to optimize PAM – a polio antigen microarray – for safe and effective measurement of protection from polio infection.
A new commentary urges public health researchers to incorporate questions about partisan identity in demographic data collection, arguing that excluding this information could lead to ineffective policy and health promotion interventions. By including partisanship in more public health surveys, researchers can better track its impact o...
Researchers at La Jolla Institute for Immunology found that people who experienced breakthrough COVID-19 infections develop T cells better equipped to recognize and target SARS-CoV-2. The study also discovered that B cells produce more diverse antibodies targeting common epitopes between the vaccine and variants.
A new Lancet Series estimates that over 750,000 deaths associated with antimicrobial resistance (AMR) could be prevented annually through improved prevention methods. AMR poses significant threats to newborns, elderly individuals, and those with chronic illnesses, causing nearly 5 million deaths globally each year.
Scientists at the University of Nottingham have created a powerful method to analyze RNA structures in unprecedented detail. By combining cryogenic OrbiSIMS with advanced computational modelling and automation, they can now determine RNA structures in a matter of days, significantly advancing the field of RNA structural biology.
The study reviews various immunotherapies for HCC, including ICIs and cellular therapies, highlighting their potential in managing advanced disease and preventing recurrence. Emerging strategies like vaccine development and oncolytic virotherapy are also discussed.
Researchers found that repeat COVID-19 vaccinations elicit cross-reactive neutralizing antibodies capable of targeting multiple SARS-CoV-2 variants and distantly related coronaviruses. The findings suggest periodic re-vaccination may help build a stock of protective antibodies against emerging variants.
The HPV vaccination programme is helping to close health inequalities in cervical cancer, with most cases prevented in more deprived groups. The study found that the vaccine reduced cervical cancer incidence rates by nearly 90% and pre-cancerous conditions by around 95% in women who received routine vaccination at 12-13 years old.
F. William Studier, a senior biophysicist at Brookhaven National Laboratory, has won the 2024 Merkin Prize in Biomedical Technology for his T7 expression technology, enabling large-scale production of RNA and proteins for biomedical research and pharmaceuticals. His work has saved millions of lives with COVID-19 mRNA vaccines.
Researchers developed a synthetic biomarker technology that can differentiate between prior Zika and dengue virus infections. The technology, using epitope surrogates, correctly identified people previously infected with Zika virus 85.3% of the time.
A third Covid vaccine dose has been shown to improve defensive antibody responses in some clinically extremely vulnerable patients. The trial found that 90% of patients who received a booster dose developed significant antibodies, but more than half of those with low initial responses saw no improvement.
Researchers have identified new cellular targets for a vaccine to treat eczema in children, which may limit the severity of symptoms and reduce antibiotic use. The study uncovered specific immune signatures in children with infected flares of eczema, providing a potential blueprint for future therapies.
A late University of Virginia School of Medicine scientist's research on the SAS1B protein could lead to new cancer treatments for multiple cancers. The discovery has the potential to selectively target cancer cells while sparing healthy tissue.
Researchers developed a new 'proactive vaccinology' approach to build vaccines before disease-causing pathogens emerge. The Quartet Nanocage vaccine trains the immune system to target specific regions of eight coronaviruses, providing broad protection against known and unknown strains.
Researchers from Wyss Institute and Harvard University developed a biomaterial vaccine that enhances and sustains lymph node expansion, leading to more effective anti-tumor responses. The vaccine formulation, based on microscale mesoporous silica rods, reprograms antigen-presenting cells to orchestrate complex immune responses.
Researchers at Duke University have developed a new vaccine strategy that targets the portion of the flu virus surface with less variability, aiming for universal and long-lasting protection. The experimental vaccine elicits an immune response focused on the stalk region, which remains consistent despite viral mutations.
A new mRNA cancer vaccine has been shown to trigger a vigorous immune response in both human patients and pet dogs with glioblastoma, the most aggressive form of brain cancer. The breakthrough treatment, which uses a personalized approach and novel delivery mechanism, demonstrates promising results in early clinical trials.
A team of researchers from MSU and Harvard Medical School has created a promising vaccine candidate for antibiotic-resistant bacteria. The vaccine targets Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA), with high levels of immunity observed in animal trials.
A rapidly spreading virus is attacking cacao trees in Ghana, resulting in harvest losses of between 15-50%. Researchers have developed a new strategy to combat the spread of the disease using mathematical data to determine safe planting distances for vaccinated trees.
Scientists have designed a synthetic antigen that can stimulate antibody production against cancer cells. The approach uses a natural protein called serum albumin to carry the antigen, reducing the need for bulky carriers and side effects.
Researchers have developed a DNA vaccine against zika virus that induces a strong immune response and protects mice from the virus. The vaccine uses genetic engineering to encode specific viral proteins and stimulates an adaptive immune response, with high levels of neutralizing antibodies produced.
Researchers at UC Riverside demonstrate a new vaccine strategy targeting a common viral genome part, eliminating the need for annual booster shots. The vaccine uses small RNA molecules to boost the immune system, making it safe for babies and those with weakened immunity.
Georgia Tech researchers have developed a trivalent vaccine that offers broad protection against not only SARS-CoV-2 variants but also other bat sarbecoviruses. The groundbreaking vaccine has shown complete protection with no trace of virus in the lungs, marking a significant step toward a universal vaccine for coronaviruses.
A second-generation melanoma vaccine has shown improved survival rates for male patients compared to female patients, particularly those who are younger and have earlier-stage cancer. The vaccine targets helper T cells to recognize melanoma proteins, leading to boosted patient survival and reduced cancer reoccurrences.
Researchers at UVA Health discovered a potential explanation for long COVID symptoms by identifying 'abzymes' that act like enzymes regulating important bodily functions. This discovery could lead to new treatments targeting these rogue antibodies to alleviate acute effects of COVID-19 and its complications.
A new study by Karolinska Institutet researchers has identified the protein on cell surfaces that the Crimean-Congo hemorrhagic fever virus uses to enter human cells. This discovery is crucial in developing effective treatments and vaccines for the deadly disease, which can cause up to 40% mortality rate.
Low HPV vaccine uptake among US adults aged 27-45 is a concern, particularly for men and Hispanic individuals. Experts stress the need to address disparities in vaccination rates to prevent cancer cases.
Developed by scientists from the University of Oxford, the LungVax vaccine uses technology similar to the highly successful Oxford/AstraZeneca COVID-19 vaccine. The vaccine will train the immune system to recognise and attack abnormal lung cells with neoantigens.
A new vaccine developed by UCLA researchers demonstrates high protection against melioidosis, a tropical disease that causes 89,000 fatalities annually. The vaccine was tested in mice and found effective even against a highly lethal strain of the bacteria.
Scientists identified key factors in developing long-lasting immunity against dengue virus through analyzing immune responses to natural infection and vaccines. The study revealed molecular markers that could be used in novel vaccine development.
Researchers found that early antibiotic treatment accelerated recovery in COVID-19 patients. The study used a combination of antibiotics, including amoxicillin and rifaximin, within the first three days of infection. This treatment significantly reduced the risk of long-term COVID symptoms.
A new multitasking substance has been identified to prevent and treat both flu and COVID-19 infections concurrently. The long-acting recombinant cytokine protein rhIL-7-hyFc demonstrated therapeutic and preventive effects against various respiratory diseases, including COVID-19, influenza virus, and respiratory syncytial virus.
A competition among researchers predicted B. pertussis vaccine responses based on a simple correlation between calendar age and antibody responses. The result highlights the need for further research to understand variability in vaccination outcomes.
Researchers developed a protein-based vaccine candidate called SpyCage that induces an immune response in rodent models, clearing COVID-19 infections more quickly than controls. The platform has the potential to prevent infection and transmission of respiratory viruses like SARS-CoV-2 by inducing a mucosal immune response.
A new study finds that the high burden of typhoid fever in sub-Saharan African countries calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines. The study estimates that there are 12.5 to 16.3 million cases of typhoid every year with 140,000 deaths.